Petros Pharmaceuticals, Inc. (PTPI)
USD 0.05
(-3.36%)
USD 0.05
(-3.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.16 Million USD | 69.81% |
| 2022 | -27.03 Million USD | -189.01% |
| 2021 | -9.35 Million USD | 54.55% |
| 2020 | -20.58 Million USD | 36.68% |
| 2019 | -32.51 Million USD | -0.12% |
| 2018 | -32.47 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -8.02 Million USD | -2623.01% |
| 2024 Q2 | -662.02 Thousand USD | 91.75% |
| 2023 Q2 | -2.54 Million USD | 98.84% |
| 2023 Q3 | -4.54 Million USD | -78.64% |
| 2023 FY | -8.16 Million USD | 69.81% |
| 2023 Q4 | 318.15 Thousand USD | 106.99% |
| 2023 Q1 | -219.4 Million USD | -5097.43% |
| 2022 FY | -27.03 Million USD | -189.01% |
| 2022 Q4 | -4.22 Million USD | 69.48% |
| 2022 Q3 | -13.83 Million USD | -604.84% |
| 2022 Q2 | -1.96 Million USD | -155.7% |
| 2022 Q1 | 3.52 Million USD | 143.03% |
| 2021 FY | -9.35 Million USD | 54.55% |
| 2021 Q4 | -8.18 Million USD | -382.41% |
| 2021 Q3 | -1.69 Million USD | 19.69% |
| 2021 Q2 | -2.11 Million USD | -170.22% |
| 2021 Q1 | 3 Million USD | 155.33% |
| 2020 FY | -20.58 Million USD | 36.68% |
| 2020 Q4 | -5.43 Million USD | -64.77% |
| 2020 Q3 | -3.3 Million USD | 42.75% |
| 2020 Q2 | -5.76 Million USD | 5.24% |
| 2020 Q1 | -6.08 Million USD | 27.81% |
| 2019 Q1 | -6.34 Million USD | 0.0% |
| 2019 Q4 | -8.42 Million USD | 7.81% |
| 2019 FY | -32.51 Million USD | -0.12% |
| 2019 Q3 | -9.14 Million USD | -6.28% |
| 2019 Q2 | -8.6 Million USD | -35.61% |
| 2018 FY | -32.47 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 116.952% |
| Embecta Corp. | 70.4 Million USD | 111.595% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 143.47% |
| Dynavax Technologies Corporation | -6.38 Million USD | -27.769% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 96.099% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 119.457% |
| PainReform Ltd. | -9.34 Million USD | 12.637% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -3.725% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -81.161% |
| SCYNEXIS, Inc. | 67.04 Million USD | 112.176% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -163.453% |
| Cosmos Health Inc. | -18.54 Million USD | 55.976% |
| Journey Medical Corporation | -3.85 Million USD | -111.866% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -81.161% |
| Safety Shot Inc | -15.08 Million USD | 45.878% |
| Alpha Teknova, Inc. | -36.78 Million USD | 77.805% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 94.156% |
| Bright Green Corporation | -13.12 Million USD | 37.817% |
| Procaps Group, S.A. | 42.54 Million USD | 119.189% |
| Theratechnologies Inc. | -23.95 Million USD | 65.926% |
| Harrow Health, Inc. | -24.41 Million USD | 66.559% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -68.835% |
| Biofrontera Inc. | -20.13 Million USD | 59.45% |
| DURECT Corporation | -27.62 Million USD | 70.449% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 720.303% |
| Cronos Group Inc. | -73.96 Million USD | 88.963% |
| OptiNose, Inc. | -35.48 Million USD | 76.994% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.186% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 80.655% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 134.133% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 265.08% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 5265.496% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -30.001% |
| Radius Health, Inc. | -25.79 Million USD | 68.349% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -32.453% |
| ProPhase Labs, Inc. | -16.78 Million USD | 51.357% |
| Phibro Animal Health Corporation | 2.41 Million USD | 437.88% |
| Procaps Group S.A. | 42.54 Million USD | 119.189% |
| Alvotech | -551.73 Million USD | 98.52% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 20.576% |
| Viatris Inc. | 54.7 Million USD | 114.924% |
| Rockwell Medical, Inc. | -8.43 Million USD | 3.268% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 48.478% |
| SIGA Technologies, Inc. | 68.06 Million USD | 111.993% |
| Tilray Brands, Inc. | -244.98 Million USD | 96.668% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 167.953% |
| Shineco, Inc. | -22.44 Million USD | 63.637% |
| PetIQ, Inc. | 2.13 Million USD | 483.068% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -89.761% |
| Incannex Healthcare Limited | -18.45 Million USD | 55.777% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 103.269% |
| Alimera Sciences, Inc. | -20.13 Million USD | 59.452% |
| Silver Spike Investment Corp. | 7.34 Million USD | 211.213% |
| Assertio Holdings, Inc. | -331.94 Million USD | 97.541% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -23.821% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 54.393% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 59.301% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 94.907% |
| Hempacco Co., Inc. | -13.12 Million USD | 37.809% |
| Talphera, Inc. | -18.39 Million USD | 55.628% |
| Alvotech | -551.73 Million USD | 98.52% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 122.903% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 102.499% |
| Currenc Group, Inc. | -15.3 Million USD | 46.669% |
| Kamada Ltd. | 8.28 Million USD | 198.542% |
| Indivior PLC | 2 Million USD | 508.159% |
| Evoke Pharma, Inc. | -7.79 Million USD | -4.76% |
| Flora Growth Corp. | -57.03 Million USD | 85.688% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 59.301% |
| Evolus, Inc. | -61.68 Million USD | 86.766% |
| HUTCHMED (China) Limited | 100.78 Million USD | 108.1% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 105.935% |
| Akanda Corp. | -32.27 Million USD | 74.707% |